Mainz Biomed BV
$ 0.61
3.45%
24 Feb - close price
- Market Cap 7,902,800 USD
- Current Price $ 0.61
- High / Low $ 0.66 / 0.55
- Stock P/E N/A
- Book Value 0.62
- EPS -5.28
- Next Earning Report 2026-04-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.14 %
- ROE -4.66 %
- 52 Week High 6.29
- 52 Week Low 0.55
About
Mainz Biomed BV is a leading biotechnology firm dedicated to pioneering advanced diagnostic solutions aimed at the early detection of cancer, particularly focusing on gastrointestinal disorders. Its flagship offering, a proprietary non-invasive colorectal cancer screening test, utilizes cutting-edge biomarker technology to enhance the accuracy and accessibility of screenings. Positioned strategically within the expanding diagnostics market, Mainz Biomed is committed to addressing critical unmet clinical needs and improving patient outcomes. With a robust intellectual property portfolio and a strong emphasis on research and development, the company is well-prepared to leverage the growing demand for efficient cancer diagnostic tools on a global scale.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-28 | 2025-09-03 | 2025-05-30 | 2025-03-31 | 2024-10-21 | 2024-06-30 | 2024-04-09 | 2024-03-06 | 2023-11-16 | 2023-08-15 | 2023-04-27 | 2023-03-08 |
| Reported EPS | 0 | -2.65 | -7.71 | -7.71 | -19.6 | None | -0.24 | -0.24 | -0.39 | -0.56 | -0.45 | -0.46 |
| Estimated EPS | -2 | -2.4 | -2.8 | -6.4 | -0.15 | -9 | -0.32 | -0.3167 | -0.47 | -0.42 | -0.46 | -0.46 |
| Surprise | 2 | -0.25 | -4.91 | -1.31 | -19.45 | 0 | 0.08 | 0.0767 | 0.08 | -0.14 | 0.01 | 0 |
| Surprise Percentage | 100% | -10.4167% | -175.3571% | -20.4688% | -12966.6667% | None% | 25% | 24.2185% | 17.0213% | -33.3333% | 2.1739% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-04-07 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYNZ
2026-02-20 08:28:05
Mainz Biomed has announced a $6.0 million private placement and provided a strategic update regarding its operations. The capital injection is intended to support the company's ongoing commercialization efforts and clinical development of its molecular diagnostic tests for cancer early detection.
2026-02-18 08:57:58
Mainz Biomed (NASDAQ:MYNZ) has secured $6 million in private placement funding and is strategically shifting its focus to pancreatic cancer detection in the U.S. The company plans to use the proceeds for operations, liabilities, and strategic initiatives, including winding down its German subsidiary and potentially selling its colorectal cancer screening assets to reduce expenses. This move comes as the micro-cap company, with a market cap of $8.64 million, seeks to stabilize its business after an 86.75% stock price drop over the past year.
2026-02-18 03:57:50
Mainz Biomed N.V. has announced a $6.0 million private placement with investor David Lazar to strengthen its liquidity and shift its strategic focus. The company will now prioritize its pancreatic cancer detection program in the U.S., while also seeking to sell its colorectal cancer screening assets and wind down its German subsidiary. This move is intended to reduce operating expenses and extend the company's financial runway.
2026-02-17 15:57:44
Mainz Biomed has secured $6 million in private placement financing and is strategically shifting its focus to pancreatic cancer detection in the United States. The company plans to wind down its German subsidiary and divest its colorectal cancer screening assets to reduce operating expenses and extend its financial runway. This move comes after its stock price plummeted by 86.75% over the past year.
2026-02-17 14:27:07
Mainz Biomed N.V. has announced a $6.0 million private placement, with $3.0 million already closed, led by investor David Lazar, who has also been named Chairman of the Board. The company plans to use the funds to strengthen its liquidity, focus on its U.S. pancreatic cancer detection program, and explore strategic alternatives, including the potential sale of its colorectal cancer screening assets and winding down its German subsidiary to reduce operating expenses. This strategic shift aims to unlock long-term value for stockholders.
2026-02-17 13:27:27
Mainz Biomed (NASDAQ:MYNZ) has secured $6 million in private placement funding and is strategically shifting its focus to the U.S. pancreatic cancer detection market. The company, facing an 86.75% stock price drop over the past year, will use the funds for operations and liabilities, while also selling its colorectal cancer screening assets and winding down its German subsidiary. David Lazar, a key investor, has been appointed Chairman of the Board as part of this realignment.
